Haemonetics
297 hedge funds and large institutions have $4.37B invested in Haemonetics in 2024 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 102 increasing their positions, 114 reducing their positions, and 40 closing their positions.
190% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $5.04M
22% more capital inflows, than outflows
Capital inflows: $378M | Capital outflows: $310M
1.09% more ownership
Funds ownership: 99.66% → 100.74% (+1.1%)
3% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 40
1% more funds holding
Funds holding: 295 → 297 (+2)
11% less repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 114
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$78.7M |
| 2 |
Silvercrest Asset Management
New York
|
+$35.6M |
| 3 |
Royce & Associates
New York
|
+$23.6M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$22.5M |
| 5 |
Neuberger Berman Group
New York
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$109M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$48.4M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$20.7M |
| 4 |
Morgan Stanley
New York
|
-$10M |
| 5 |
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$5.89M |
HAE Hedge Fund Activity: Q1 2024 in Review
297 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2024, worth a combined $4.37B — up 0.97% from $4.32B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new HAE positions and 40 closed out — a net gain of 1 holder — while 102 added to existing stakes and 114 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $78.7M. The largest seller was Fidelity Investments, cutting an estimated $109M.
- 297 institutional investors held Haemonetics (HAE) as of Q1 2024, up from 295 in Q4 2023.
- Funds reported $4.37B of Haemonetics stock for Q1 2024, up 0.97% quarter-over-quarter.
- 41 funds opened new Haemonetics positions in Q1 2024 and 40 closed out, a net change of +1 holder.
- The largest Haemonetics buyer in Q1 2024 was Wellington Management Group, an estimated $78.7M added.
- The largest Haemonetics seller in Q1 2024 was Fidelity Investments, an estimated $109M sold.
Based on aggregated 13F filings for Q1 2024.